Published in Clin Cancer Res on March 12, 2014
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol (2014) 1.76
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. J Clin Oncol (2015) 1.73
A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature (2015) 1.66
The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Med (2014) 1.16
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res (2016) 1.01
Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome Biol (2014) 0.92
A river model to map convergent cancer evolution and guide therapy in RCC. Nat Rev Urol (2015) 0.91
Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. Front Oncol (2014) 0.85
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. Oncologist (2016) 0.85
Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies. Front Oncol (2015) 0.83
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Oncotarget (2016) 0.81
Precision medicine from the renal cancer genome. Nat Rev Nephrol (2016) 0.80
Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma. BMC Med (2016) 0.80
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. J Natl Compr Canc Netw (2016) 0.80
The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma. Cell Rep (2017) 0.79
Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. Mol Cancer Res (2016) 0.78
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nat Commun (2016) 0.77
A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med (2017) 0.76
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. J Clin Invest (2016) 0.76
Novel drugs that target the metabolic reprogramming in renal cell cancer. Cancer Metab (2016) 0.76
Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients? J Cancer (2016) 0.76
Cancer diagnostics: The journey from histomorphology to molecular profiling. Oncotarget (2016) 0.75
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. Oncotarget (2016) 0.75
Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma. Transl Oncol (2016) 0.75
mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses? EBioMedicine (2014) 0.75
Strategies to overcome therapeutic resistance in renal cell carcinoma. Urol Oncol (2017) 0.75
Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making? Cancer (2016) 0.75
Seeing the forest for the trees: kidney oncogenomes in relation to therapeutic outcomes. Clin Cancer Res (2014) 0.75
Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact. Curr Opin Urol (2016) 0.75
A braided cancer river connects tumor heterogeneity and precision medicine. Clin Transl Med (2016) 0.75
Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia. Pediatr Blood Cancer (2016) 0.75
Discovering Biomarkers within the Genomic Landscape of Renal Cell Carcinoma. J Kidney (2016) 0.75
Delayed Cytoreductive Nephrectomy Following Three Years of Targeted Therapy for Metastatic Renal Cell Carcinoma. Curr Urol (2016) 0.75
Functional precision cancer medicine-moving beyond pure genomics. Nat Med (2017) 0.75
Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. Eur Urol Focus (2016) 0.75
Targeted therapies for renal cell carcinoma. Nat Rev Nephrol (2017) 0.75
Exceptional Durable Response to Everolimus in a Patient with Biphenotypic Breast Cancer Harboring an STK11 Variant. Cold Spring Harb Mol Case Stud (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
mTOR signaling in growth control and disease. Cell (2012) 29.21
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med (2010) 8.28
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
Renal cell carcinoma. Lancet (2009) 6.92
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell (2012) 5.62
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol (2004) 4.67
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res (2009) 3.59
Intratumor heterogeneity: evolution through space and time. Cancer Res (2012) 3.45
Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med (2012) 3.38
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer (2007) 3.00
mTOR kinase structure, mechanism and regulation. Nature (2013) 2.80
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med (2013) 2.66
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 2.26
Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol (2009) 2.05
A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer (2009) 1.66
Of cancer and cave fish. Nat Rev Cancer (2011) 1.50
Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov (2012) 1.50
The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res (2011) 1.34
Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res (2011) 1.33
The GIST paradigm: lessons for other kinase-driven cancers. J Pathol (2010) 1.26
Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer (2009) 1.21
Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol (2011) 1.09
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. Med Oncol (2010) 0.91
Human MicroRNA targets. PLoS Biol (2004) 34.51
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Integration of biological networks and gene expression data using Cytoscape. Nat Protoc (2007) 27.10
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
MicroRNA targets in Drosophila. Genome Biol (2003) 23.59
Global mapping of the yeast genetic interaction network. Science (2004) 21.34
International network of cancer genome projects. Nature (2010) 20.35
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
The microRNA.org resource: targets and expression. Nucleic Acids Res (2007) 16.26
The HUPO PSI's molecular interaction format--a community standard for the representation of protein interaction data. Nat Biotechnol (2004) 16.08
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Characterizing gene sets with FuncAssociate. Bioinformatics (2003) 14.10
Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature (2012) 13.71
Identification of microRNAs of the herpesvirus family. Nat Methods (2005) 12.98
Identification of virus-encoded microRNAs. Science (2004) 12.56
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res (2011) 10.99
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science (2003) 9.55
The BioPAX community standard for pathway data sharing. Nat Biotechnol (2010) 9.19
Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res (2010) 9.18
Diversity and complexity in DNA recognition by transcription factors. Science (2009) 9.07
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol (2002) 9.05
A novel class of small RNAs bind to MILI protein in mouse testes. Nature (2006) 8.80
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
The Systems Biology Graphical Notation. Nat Biotechnol (2009) 8.53
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (2011) 7.22
Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol (2010) 7.15
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature (2009) 7.04
Computational identification of microRNA targets. Dev Biol (2004) 6.84
Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A (2007) 6.79
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
Emerging landscape of oncogenic signatures across human cancers. Nat Genet (2013) 6.48
miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol (2004) 6.44
Rapid analysis of the DNA-binding specificities of transcription factors with DNA microarrays. Nat Genet (2004) 6.33
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Pathguide: a pathway resource list. Nucleic Acids Res (2006) 6.05
Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science (2002) 5.89
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? J Urol (2008) 5.70
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Human ES cell-derived neural rosettes reveal a functionally distinct early neural stem cell stage. Genes Dev (2008) 5.34
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
High-resolution DNA-binding specificity analysis of yeast transcription factors. Genome Res (2009) 5.11
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol (2006) 5.10
Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest (2010) 4.95
MicroRNA profiling of the murine hematopoietic system. Genome Biol (2005) 4.94
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J (2010) 4.78
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A (2008) 4.76
Protein 3D structure computed from evolutionary sequence variation. PLoS One (2011) 4.71
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol (2004) 4.68
Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data. Genome Biol (2013) 4.67
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2011) 4.52
Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev (2009) 4.43
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol (2007) 4.40
Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4.35
Functional copy-number alterations in cancer. PLoS One (2008) 4.27